NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
by National Institutes of Health
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional), run by National Institutes of Health, offers non-dilutive federal R&D funding for small businesses. Applications close Apr 5, 2029 · time not confirmed.
Benefits
Non-dilutive federal R&D funding for small businesses
Eligibility
Only United States small business concerns (SBCs) that have previously received an NIH SBIR or STTR Phase II award are eligible to submit applications for this opportunity. Only one NIH Phase IIB Strategic Breakthrough award is allowed per project.
Open to: United States
Timeline
- Opens
- May 28, 2026
- Deadline
- Apr 5, 2029 · time not confirmed
- Recurring
- Annual · next expected May 28, 2027
- Fee
- None
Questions and answers
When is the deadline for NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)?
The deadline is Apr 5, 2029 · time not confirmed. The organizer does not state a time, so OSH treats it as the end of that day anywhere on Earth.
Who can apply to NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)?
Only United States small business concerns (SBCs) that have previously received an NIH SBIR or STTR Phase II award are eligible to submit applications for this opportunity. Only one NIH Phase IIB Strategic Breakthrough award is allowed per project.
What does NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) offer?
Non-dilutive federal R&D funding for small businesses.
Is there an application fee?
None
Sources
- 1.Grants.gov — May 28, 2026 · Official